If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,060.00    -188.00 (-8.36%)
Bid:
2,074.00
Ask:
2,084.00
Spread: 10.00 (0.482%)
Market Cap: £1.37b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
 

20 September 2011

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price of 1,000 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 45,856 Ordinary Shares which represents 0.08% of the issued share capital of the Company which is currently 60,239,150 Ordinary Shares.

 

Genus also announces that of 46,927 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 46,927 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 1,000 pence per Ordinary Share.

 

Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 41,061 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 1,000 pence per Ordinary Share.

 

Thomas Philip Acton's direct shareholding in the Company now stands at 31,104 Ordinary Shares which represents 0.06% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 1,000 pence per Ordinary Share.

 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost options under the Plan.

 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSURRSRANAKUAR
Date   Source Headline
2nd Apr 200812:00 pmRNSMerger Update
1st Apr 20085:33 pmRNSDirector/PDMR Shareholding
31st Mar 20084:00 pmRNSTotal Voting Rights
31st Mar 20084:00 pmRNSBlocklisting Interim Review
20th Mar 20082:08 pmRNSHolding(s) in Company
17th Mar 20083:21 pmRNSHolding(s) in Company
13th Mar 20082:00 pmRNSHolding(s) in Company
29th Feb 20082:00 pmRNSTotal Voting Rights
27th Feb 20085:02 pmRNSDirector/PDMR Shareholding
26th Feb 20084:54 pmRNSDirector/PDMR Shareholding
26th Feb 20087:00 amRNSInterim Results
22nd Feb 200811:56 amRNSHolding(s) in Company
31st Jan 20082:00 pmRNSBlocklisting Interim Review
17th Jan 20087:00 amRNSBoard Changes
15th Jan 20088:00 amRNS1st dealings on AIM
15th Jan 20088:00 amRNSDisposal
14th Jan 20085:40 pmRNSHolding(s) in Company
9th Jan 200811:00 amRNSAppointment of New Adviser
2nd Jan 20083:15 pmRNSTotal Voting Rights
30th Nov 20078:00 amRNSTotal Voting Rights
27th Nov 20077:01 amRNSDisposal
15th Nov 20073:39 pmRNSResult of AGM
15th Nov 20077:01 amRNSAGM Statement
12th Nov 20078:24 amRNSAdmission to Official List
12th Nov 20078:00 amRNSCancellation - 12/11/2007
7th Nov 20077:57 amRNSPublication of Prospectus
6th Nov 200712:51 pmRNSHolding(s) in Company
6th Nov 20077:00 amRNSDisposal
1st Nov 20075:53 pmRNSDirector/PDMR Shareholding
1st Nov 20077:02 amRNSPlacing
31st Oct 20079:20 amRNSTotal Voting Rights
18th Oct 20072:30 pmRNSDirector/PDMR Shareholding
12th Oct 20077:01 amRNSMove to the Official List
4th Oct 20077:01 amRNSDisposal of SyAqua Mexico
28th Sep 20077:01 amRNSTotal Voting Rights
24th Sep 20072:11 pmRNSDirector/PDMR Shareholding
18th Sep 20077:02 amRNSPreliminary Results
12th Sep 20072:55 pmRNSStatement re: Foot & Mouth
5th Sep 20075:16 pmRNSBlocklisting Interim Review
17th Aug 20072:55 pmRNSChange of Adviser
10th Aug 20074:28 pmRNSAIM Rule 26
6th Aug 20077:01 amRNSStatement Re: Foot & Mouth
25th Jul 20072:00 pmRNSBlocklisting Interim Review
18th Jul 20077:01 amRNSPre-Close Trading Update
7th Jun 20076:35 pmRNSHolding(s) in Company
7th Jun 20076:33 pmRNSHolding(s) in Company
19th Apr 20075:13 pmRNSDirector/PDMR Shareholding
12th Apr 200710:58 amRNSHolding(s) in Company
29th Mar 20077:00 amRNSHolding(s) in Company
13th Mar 20077:02 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.